BrP-LPA acts as both an Autotaxin inhibitor (94% inhibition at 10 µM) and pan LPA receptor antagonist (LPA1: 1.5 µM, LPA2: 1.4 µM, LPA3: 1.2 µM, LPA4: 0.27 µM). BrP-LPA inhibits the invasiveness of NIH3T3 ras ATX cells by 40% and decreases chemotaxis by 23%. BrP-LPA reduces the size of breast (MDA-MB-231), colon (HCT-116) and melanoma (B16F10) tumors in mouse models. It also attenuates collagen-induced arthritis PPARgamma is not activated by BrP-LPA.